Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The effects of increased serotonergic activity on human sensory gating and its neural generators

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{c368402e18bf48cc9c14c3a8f7c7e1b5,
title = "The effects of increased serotonergic activity on human sensory gating and its neural generators",
abstract = "RATIONALE: Schizophrenia is a disabling illness with deficits in core mental functions such as sensory gating. The P50 amplitude is an (usually auditory) evoked brain potential that, in a so-called double-click paradigm, can be used to quantify sensory gating. Reports on serotonergic modulation of P50 suppression are sparse.OBJECTIVE: The objective of this study was to study the effects of increased serotonergic activity on parameters of P50 suppression in healthy volunteers.MATERIALS AND METHODS: In a double-blind placebo-controlled crossover design, 21 healthy male volunteers received either placebo or a dose of 10 mg of escitalopram (selective serotonin reuptake inhibitor), after which they were tested in a P50 suppression paradigm. Furthermore, an attempt was made to identify the neural generators of the P50 evoked potential.RESULTS: Escitalopram did not affect P50 suppression but was found to increase P50 amplitude to the first (or conditioning) stimulus. Two bilateral sources located in the temporal cortex, two bilaterally located near the eyes, and one in a fronto-central location were identified, the latter correlating positively with the P50 amplitude.CONCLUSIONS: In the current study, escitalopram did not affect P50 suppression in healthy male volunteers, which indicates that sensory gating is not affected by a nonspecific increase in serotonergic activity. Furthermore, a generator with a fronto-central location in the brain (possibly the anterior cingulate) was found to be the primary source of the P50 evoked potential.",
keywords = "Acoustic Stimulation, Adult, Analysis of Variance, Brain, Citalopram, Cross-Over Studies, Double-Blind Method, Electroencephalography, Evoked Potentials, Auditory, Frontal Lobe, Habituation, Psychophysiologic, Humans, Male, Neural Pathways, Serotonin Uptake Inhibitors, Journal Article, Research Support, Non-U.S. Gov't",
author = "Frederiksen, {Kristian Steen} and Bob Oranje and Malene Wienberg and Glenth{\o}j, {Birte Y}",
year = "2008",
month = "3",
doi = "10.1007/s00213-007-1001-y",
language = "English",
volume = "196",
pages = "631--41",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer",
number = "4",

}

RIS

TY - JOUR

T1 - The effects of increased serotonergic activity on human sensory gating and its neural generators

AU - Frederiksen, Kristian Steen

AU - Oranje, Bob

AU - Wienberg, Malene

AU - Glenthøj, Birte Y

PY - 2008/3

Y1 - 2008/3

N2 - RATIONALE: Schizophrenia is a disabling illness with deficits in core mental functions such as sensory gating. The P50 amplitude is an (usually auditory) evoked brain potential that, in a so-called double-click paradigm, can be used to quantify sensory gating. Reports on serotonergic modulation of P50 suppression are sparse.OBJECTIVE: The objective of this study was to study the effects of increased serotonergic activity on parameters of P50 suppression in healthy volunteers.MATERIALS AND METHODS: In a double-blind placebo-controlled crossover design, 21 healthy male volunteers received either placebo or a dose of 10 mg of escitalopram (selective serotonin reuptake inhibitor), after which they were tested in a P50 suppression paradigm. Furthermore, an attempt was made to identify the neural generators of the P50 evoked potential.RESULTS: Escitalopram did not affect P50 suppression but was found to increase P50 amplitude to the first (or conditioning) stimulus. Two bilateral sources located in the temporal cortex, two bilaterally located near the eyes, and one in a fronto-central location were identified, the latter correlating positively with the P50 amplitude.CONCLUSIONS: In the current study, escitalopram did not affect P50 suppression in healthy male volunteers, which indicates that sensory gating is not affected by a nonspecific increase in serotonergic activity. Furthermore, a generator with a fronto-central location in the brain (possibly the anterior cingulate) was found to be the primary source of the P50 evoked potential.

AB - RATIONALE: Schizophrenia is a disabling illness with deficits in core mental functions such as sensory gating. The P50 amplitude is an (usually auditory) evoked brain potential that, in a so-called double-click paradigm, can be used to quantify sensory gating. Reports on serotonergic modulation of P50 suppression are sparse.OBJECTIVE: The objective of this study was to study the effects of increased serotonergic activity on parameters of P50 suppression in healthy volunteers.MATERIALS AND METHODS: In a double-blind placebo-controlled crossover design, 21 healthy male volunteers received either placebo or a dose of 10 mg of escitalopram (selective serotonin reuptake inhibitor), after which they were tested in a P50 suppression paradigm. Furthermore, an attempt was made to identify the neural generators of the P50 evoked potential.RESULTS: Escitalopram did not affect P50 suppression but was found to increase P50 amplitude to the first (or conditioning) stimulus. Two bilateral sources located in the temporal cortex, two bilaterally located near the eyes, and one in a fronto-central location were identified, the latter correlating positively with the P50 amplitude.CONCLUSIONS: In the current study, escitalopram did not affect P50 suppression in healthy male volunteers, which indicates that sensory gating is not affected by a nonspecific increase in serotonergic activity. Furthermore, a generator with a fronto-central location in the brain (possibly the anterior cingulate) was found to be the primary source of the P50 evoked potential.

KW - Acoustic Stimulation

KW - Adult

KW - Analysis of Variance

KW - Brain

KW - Citalopram

KW - Cross-Over Studies

KW - Double-Blind Method

KW - Electroencephalography

KW - Evoked Potentials, Auditory

KW - Frontal Lobe

KW - Habituation, Psychophysiologic

KW - Humans

KW - Male

KW - Neural Pathways

KW - Serotonin Uptake Inhibitors

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1007/s00213-007-1001-y

DO - 10.1007/s00213-007-1001-y

M3 - Journal article

VL - 196

SP - 631

EP - 641

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -

ID: 49918722